Immune responsiveness to tuberculin in vitro may predict clinical outcome of intravesical BCG immunotherapy in bladder cancer

2017 ◽  
Vol 16 (3) ◽  
pp. e1679-e1680
Author(s):  
S. Jallad ◽  
D. Thomas ◽  
P. Thomas ◽  
M. Newport ◽  
F. Kern
Keyword(s):  
Bladder Cancer ◽  
Clinical Outcome ◽  
Immune Responsiveness ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

scholarly journals Disseminated BCG Infection after intravesical BCG Immunotherapy of Bladder Cancer

QJM ◽  
2021 ◽  
Author(s):  
S Ramalingam ◽  
K Gunasekaran ◽  
H Arora ◽  
M Muruganandam ◽  
S Nagaraju ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

T-Cell Subsets Required for Intravesical BCG Immunotherapy for Bladder Cancer

1993 ◽  
Vol 150 (3) ◽  
pp. 1018-1023 ◽  
Author(s):  
Timothy L. Ratliff ◽  
Julie K. Ritchey ◽  
Jerry J.J. Yuan ◽  
Gerald L. Andriole ◽  
William J. Catalona
Keyword(s):  
Bladder Cancer ◽  
T Cell ◽  
T Cell Subsets ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

scholarly journals Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Yuqing Liu ◽  
Jian Lu ◽  
Yi Huang ◽  
Lulin Ma
Keyword(s):  
Bladder Cancer ◽  
Adverse Reactions ◽  
Clinical Manifestations ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Proven Efficacy ◽  
Bcg Instillation ◽  
Early Establishment

Because of its proven efficacy, intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is an important treatment for nonmuscle invasive bladder cancer at high risk of recurrence or progression. However, approximately 8% of patients have to stop BCG instillation as a result of its complications. Complications induced by BCG therapy can have a variety of clinical manifestations. These adverse reactions may occur in conjunction with BCG instillation or may not develop until months or years after BCG cessation. An essential step in the management complications arising from BCG is early establishment of diagnosis, particularly for distant, disseminated, and obscure infections. Therefore we reviewed the literature on the potential complications after intravesical BCG immunotherapy for bladder cancer and provide an overview on the incidence, diagnosis, and treatment modality of genitourinary and systemic BCG-induced complications.

CASE REPORT Reactive arthritis after application of intravesical BCG immunotherapy in bladder cancer

2009 ◽  
Vol 62 ◽  
pp. 266-267
Author(s):  
Artur Chmiel ◽  
Joanna Wierzbicka-Chmiel ◽  
Krzysztof Wierzbicki ◽  
Tadeusz Dzielski ◽  
Jolanta Gil
Keyword(s):  
Bladder Cancer ◽  
Case Report ◽  
Reactive Arthritis ◽  
Bcg Immunotherapy ◽  
Intravesical Bcg

scholarly journals Mycobacterial Brain Tuberculomas due to Bacille Calmette-Guérin Intravesical Chemotherapy for Bladder Cancer: A Case Report and Literature Review

2011 ◽  
Vol 22 (3) ◽  
pp. 104-106 ◽  
Author(s):  
Vitaly Golub ◽  
Prashant Malhotra ◽  
Shital Patel
Keyword(s):  
Central Nervous System ◽  
Bladder Cancer ◽  
Nervous System ◽  
Superficial Bladder Cancer ◽  
Present Report ◽  
Bacille Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy

Bacille Calmette-Guérin (BCG) immunotherapy is widely used for the treatment of superficial bladder cancer. The authors believe that the present report is one of the first to document cerebral BCG tuberculoma in a 73-year-old immunocompetent man, three years after intra-vesical BCG immunotherapy. His workup revealed no identifiable extracranial source. He responded well to treatment with rifampin, ethambutol and moxifloxacin.Patients undergoing intravesical BCG therapy should be closely monitored for the development of this complication. Prolonged antitubercular therapy, possibly including moxifloxacin, appears to be beneficial in the treatment of central nervous system tuberculous infections.

scholarly journals Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Hakeem Sam ◽  
Mary M Stevenson
Keyword(s):  
Bladder Cancer ◽  
Peritoneal Lavage ◽  
Compositional Analysis ◽  
Tumor Cell Line ◽  
In Vitro Cytotoxicity ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Key Points ◽  
The Difference

In this study, we investigated host response to Bacillus-Calmette Guérin (BCG) immunotherapy using the murine MM45T bladder tumor cell line. BALB/c (Bcgs allele) and BALB/c.CD2 (CD2) (Bcgr allele) mice were seeded subcutaneously with MM45T cells. Treatment began on day 7 with intra-tumor injections of BCG. Significant decreases in tumor growth in BALB/c (p < 0.05) but not in the CD2 (p = NS) mice were observed 6, 10 and 14 days following treatment. Investigation of the mechanism(s) underlining the difference in the response between the two strains of mice revealed key points, namely: (i) Intraperitoneal injection of BCG led to a significant increase (p < 0.05) in the number of cells recovered 14 days later by peritoneal lavage (in million cells: 5.1 ± 0.7 vs 9.5 ± 0.3 in BALB/c and 5.3 ± 0.4 vs 7.0 ± 0.4 in CD2, PBS vs BCG). (ii) Compositional analysis of the lavages following BCG injection indicated a significant increase in the lymphocyte/macrophage ratio in BALB/c mice as compared to CD2 mice (p < 0.05). (iii) Activated peritoneal macrophage production of nitric oxide (NO) was significantly lower (p < 0.05) in BALB/c than in CD2 (26.8 ± 1.6 vs 38.3 ± 0.7 uM of nitrite respectively) when challenged with lipopolysaccharide. (iv) No difference in the in vitro cytotoxicity against MM45T cells was observed between BALB/c and CD2 macrophages. Our results suggest that differences in the composition of monocytes infiltrating the site of BCG treatment and in the release of substances such as NO by macrophages may be key determinants of the response to BCG immunotherapy for bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document